GLP‐1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities

The discoveries of the incretin hormone glucagon‐like peptide‐1 (GLP‐1) and the β‐cell hormone amylin have translated into hormone‐based therapies for diabetes. Both classes of molecules also exhibit weight‐lowering effects and have been investigated for their anti‐obesity potential. In the present review, we explore the mechanisms underlying the physiological and pharmacological actions of GLP‐1 and amylin agonism. Despite their similarities (e.g. both molecular classes slow gastric emptying, decrease glucagon and inhibit food intake), there are important distinctions between the central and/or peripheral pathways that mediate their effects on glycaemia and energy balance. We suggest that understanding the similarities and differences between these molecules holds important implications for the development of novel, combination‐based therapies, which are increasingly the norm for diabetes/metabolic disease. Finally, the future of GLP‐1‐ and amylin agonist‐based therapeutics is discussed.

[1]  P. Sexton,et al.  Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug Screening , 2010, Molecular Pharmacology.

[2]  W. Banks,et al.  Differential Permeability of the Blood–Brain Barrier to Two Pancreatic Peptides: Insulin and Amylin , 1998, Peptides.

[3]  B. Roland,et al.  Noradrenergic neurons of the area postrema mediate amylin's hypophagic action. , 2010, American journal of physiology. Regulatory, integrative and comparative physiology.

[4]  K. Laugero,et al.  Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.

[5]  M. Cowley,et al.  GLP-1 analogs: satiety without malaise? , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.

[6]  Hyunju Chung,et al.  Acute effects of glucagon-like peptide-1 on hypothalamic neuropeptide and AMP activated kinase expression in fasted rats. , 2008, Endocrine journal.

[7]  S. Woods,et al.  University of Groningen Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats , 2002 .

[8]  J. Holst,et al.  Glucagon-Like Peptide I Receptors in the Subfornical Organ and the Area Postrema Are Accessible to Circulating Glucagon-Like Peptide I , 1996, Diabetes.

[9]  T. Rink,et al.  High affinity amylin binding sites in rat brain. , 1993, Molecular pharmacology.

[10]  J. Schrezenmeir,et al.  Biological activity of GLP-1-analogues with N-terminal modifications , 1999, Regulatory Peptides.

[11]  J. Reubi,et al.  GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting , 2007, Journal of Nuclear Medicine.

[12]  E. Gao,et al.  Expression of calcitonin gene-related peptide type 1 receptor mRNA and their activity-modifying proteins in the rat nucleus accumbens , 2004, Neuroscience Letters.

[13]  B. Roland,et al.  Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight , 2010, International Journal of Obesity.

[14]  E. Ravussin,et al.  Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach to Obesity Pharmacotherapy , 2009, Obesity.

[15]  D. Parkes,et al.  Mechanisms of amylin/leptin synergy in rodent models. , 2010, Endocrinology.

[16]  C. Betsholtz,et al.  Increased insulin secretion and glucose tolerance in mice lacking islet amyloid polypeptide (amylin). , 1998, Biochemical and biophysical research communications.

[17]  C. Strader,et al.  Cloning and functional expression of a human glucagon-like peptide-1 receptor. , 1993, Biochemical and biophysical research communications.

[18]  G. Dailey,et al.  Amylin concentrations and glucose control , 1992, The Lancet.

[19]  J. Egan,et al.  Mechanisms of action of glucagon-like peptide 1 in the pancreas. , 2007, Pharmacology & therapeutics.

[20]  T. Lutz,et al.  Infusion of the amylin antagonist AC 187 into the area postrema increases food intake in rats , 2004, Physiology & Behavior.

[21]  S. Woods,et al.  A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. , 2009, Nature chemical biology.

[22]  B. Apenteng,et al.  Effects of Exendin‐4 Alone and With Peptide YY3–36 on Food Intake and Body Weight in Diet‐Induced Obese Rats , 2011, Obesity.

[23]  J. Fischer,et al.  Tests of adipsia and conditioned taste aversion following the intrahypothalamic injection of amylin , 1992, Peptides.

[24]  P. Shughrue,et al.  Distribution of pre‐pro‐glucagon and glucagon‐like peptide‐1 receptor messenger RNAs in the rat central nervous system , 1999, The Journal of comparative neurology.

[25]  Xia Li,et al.  Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. , 2000, American journal of physiology. Regulatory, integrative and comparative physiology.

[26]  T. Lutz,et al.  Diet-derived nutrients mediate the inhibition of hypothalamic NPY neurons in the arcuate nucleus of mice during refeeding. , 2009, American journal of physiology. Regulatory, integrative and comparative physiology.

[27]  A. Young Inhibition of insulin secretion. , 2005, Advances in pharmacology.

[28]  J. Cassidy,et al.  Pharmacokinetics and Pharmacodynamics of Inhaled GLP‐1 (MKC253): Proof‐of‐Concept Studies in Healthy Normal Volunteers and in Patients With Type 2 Diabetes , 2010, Clinical pharmacology and therapeutics.

[29]  K. Browning,et al.  Vagally mediated effects of glucagon‐like peptide 1: in vitro and in vivo gastric actions , 2009, The Journal of physiology.

[30]  P. MacDonald,et al.  Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. , 1999, Diabetes.

[31]  Francis S. Willard,et al.  Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets , 2010, Diabetes.

[32]  J. Holst,et al.  Neuroprotective properties of GLP-1: theoretical and practical applications , 2011, Current medical research and opinion.

[33]  D. Parkes,et al.  Insights into amylin–leptin synergy , 2010, Trends in Endocrinology & Metabolism.

[34]  Tanya Hansotia,et al.  GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice , 2005, Regulatory Peptides.

[35]  D. Richard,et al.  Lesions of area postrema and subfornical organ alter exendin-4-induced brain activation without preventing the hypophagic effect of the GLP-1 receptor agonist. , 2010, American journal of physiology. Regulatory, integrative and comparative physiology.

[36]  Melanie G. Lee,et al.  RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor , 1998, Nature.

[37]  D. Parkes,et al.  “Weighing in” on synergy: Preclinical research on neurohormonal anti-obesity combinations , 2010, Brain Research.

[38]  A. Kelley,et al.  Amylin infusion into rat nucleus accumbens potently depresses motor activity and ingestive behavior. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

[39]  P. Rorsman,et al.  Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential. , 2004, Basic & clinical pharmacology & toxicology.

[40]  R. Travagli,et al.  Glucagon-like peptide-1 excites pancreas-projecting preganglionic vagal motoneurons. , 2007, American journal of physiology. Gastrointestinal and liver physiology.

[41]  A. Young,et al.  Synergy between amylin and cholecystokinin for inhibition of food intake in mice , 1998, Physiology & Behavior.

[42]  A. Kingsbury,et al.  Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease , 2008, Journal of Neuroinflammation.

[43]  E. Bojanowska,et al.  Interactions between leptin and exendin-4, a glucagon-like peptide-1 agonist, in the regulation of food intake in the rat. , 2007, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[44]  J. Holst,et al.  Involvement of endogenous glucagon-like peptide-1 in regulation of gastric motility and pancreatic endocrine secretion , 2011, Scandinavian journal of gastroenterology.

[45]  J. Holst,et al.  The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. , 1997, Gut.

[46]  M. Castelli,et al.  Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects. , 2010, The American journal of clinical nutrition.

[47]  A. Young,et al.  Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas. , 2001, American journal of physiology. Endocrinology and metabolism.

[48]  R. Seeley,et al.  The Diverse Roles of Specific GLP-1 Receptors in the Control of Food Intake and the Response to Visceral Illness , 2002, The Journal of Neuroscience.

[49]  D. Drucker,et al.  Effects of Aging and a High Fat Diet on Body Weight and Glucose Tolerance in Glucagon-Like Peptide-1 Receptor-/- Mice. , 1998, Endocrinology.

[50]  K. Almholt,et al.  Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. , 2010, Endocrinology.

[51]  D. Drucker,et al.  Glucagon-Like Peptide-1-Responsive Catecholamine Neurons in the Area Postrema Link Peripheral Glucagon-Like Peptide-1 with Central Autonomic Control Sites , 2003, The Journal of Neuroscience.

[52]  R. Unger,et al.  Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment. , 1990, The Journal of clinical investigation.

[53]  J. Morley,et al.  Amylin and Food Intake in Mice: Effects on Motivation to Eat and Mechanism of Action , 1997, Pharmacology Biochemistry and Behavior.

[54]  J. Wishart,et al.  Evaluation of interactions between CCK and GLP-1 in their effects on appetite, energy intake, and antropyloroduodenal motility in healthy men. , 2005, American journal of physiology. Regulatory, integrative and comparative physiology.

[55]  N. Greig,et al.  Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. , 2005, Current Alzheimer research.

[56]  M. Mattson,et al.  Modulation of taste sensitivity by GLP‐1 signaling , 2008, Journal of neurochemistry.

[57]  M. Mattson,et al.  GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism , 2009, Proceedings of the National Academy of Sciences.

[58]  C. Weyer,et al.  Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity. , 2007, Endocrinology.

[59]  S. Bloom,et al.  Gut–brain cross-talk in appetite regulation , 2010, Current opinion in clinical nutrition and metabolic care.

[60]  T. Moran,et al.  Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates. , 2010, American journal of physiology. Regulatory, integrative and comparative physiology.

[61]  P. Rorsman,et al.  New insights into the regulation of glucagon secretion by glucagon-like peptide-1. , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[62]  P. Flatt,et al.  Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. , 2004, Current pharmaceutical design.

[63]  G. Edwards,et al.  Lesion of the lateral parabrachial nucleus attenuates the anorectic effect of peripheral amylin and CCK , 2007, Brain Research.

[64]  M. W. Schwartz,et al.  Central nervous system control of food intake and body weight , 2006, Nature.

[65]  E. Tomás,et al.  GLP-1-derived nonapeptide GLP-1(28–36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes , 2011, Regulatory Peptides.

[66]  S. Woods,et al.  Differences in the Central Anorectic Effects of Glucagon-Like Peptide-1 and Exendin-4 in Rats , 2009, Diabetes.

[67]  C. Weyer,et al.  Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms. , 2008, Endocrinology.

[68]  F. Ehrensperger,et al.  Lesion of the Area Postrema/Nucleus of the Solitary Tract (AP/NTS) Attenuates the Anorectic Effects of Amylin and Calcitonin Gene-Related Peptide (CGRP) in Rats , 1998, Peptides.

[69]  A. Niijima,et al.  Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. , 1996, The American journal of physiology.

[70]  J. Holst,et al.  Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. , 2004, Diabetes.

[71]  Jung-Mo Ahn,et al.  Development of potent glucagon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges. , 2010, Journal of medicinal chemistry.

[72]  J. Holst,et al.  Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. , 2002, The Journal of clinical endocrinology and metabolism.

[73]  P. Mukherjee,et al.  Complement anaphylatoxin C5a neuroprotects through regulation of glutamate receptor subunit 2 in vitro and in vivo , 2008, Journal of Neuroinflammation.

[74]  A. Turner,et al.  The role of the calcitonin receptor in protecting against induced hypercalcemia is mediated via its actions in osteoclasts to inhibit bone resorption. , 2011, Bone.

[75]  L. Orci,et al.  Paracrinology of islets and the paracrinopathy of diabetes , 2010, Proceedings of the National Academy of Sciences.

[76]  T. Lutz,et al.  Brainstem mechanisms of amylin-induced anorexia , 2010, Physiology & Behavior.

[77]  D. Drucker,et al.  Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance. , 2010, Endocrinology.

[78]  N. Rowland,et al.  Area postrema and the anorectic actions of dexfenfluramine and amylin , 1999, Brain Research.

[79]  R. Goodman,et al.  Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[80]  A. Young Inhibition of gastric emptying. , 2005, Advances in pharmacology.

[81]  Karen L Jones,et al.  Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. , 2010, The Journal of clinical endocrinology and metabolism.

[82]  J. Holst,et al.  An overview of once‐weekly glucagon‐like peptide‐1 receptor agonists—available efficacy and safety data and perspectives for the future , 2011, Diabetes, obesity & metabolism.

[83]  H. Grill,et al.  Hindbrain Cocaine- and Amphetamine-Regulated Transcript Induces Hypothermia Mediated by GLP-1 Receptors , 2009, The Journal of Neuroscience.

[84]  E. Scharrer,et al.  Anorectic effect of amylin is not transmitted by capsaicin-sensitive nerve fibers. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.

[85]  A. Jansson,et al.  Gastric emptying in response to IAPP and CCK in rats with subdiaphragmatic afferent vagotomy , 2008, Regulatory Peptides.

[86]  G. Rechkemmer,et al.  Peripheral amylin activates circumventricular organs expressing calcitonin receptor a/b subtypes and receptor-activity modifying proteins in the rat , 2004, Brain Research.

[87]  Shaoping Deng,et al.  Cloning and Functional Expression of the Human Islet GLP-1 Receptor: Demonstration That Exendin-4 Is an Agonist and Exendin-(9–39) an Antagonist of the Receptor , 1993, Diabetes.

[88]  C. Beglinger,et al.  Interaction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men. , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.

[89]  Diana L. Williams,et al.  Minireview: finding the sweet spot: peripheral versus central glucagon-like peptide 1 action in feeding and glucose homeostasis. , 2009, Endocrinology.

[90]  Michael W. Schwartz,et al.  Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. , 2009, Endocrinology.

[91]  P. J. Larsen,et al.  Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. , 1998, Diabetes.

[92]  D. Drucker,et al.  Leptin Sensitivity in Nonobese Glucagon-Like Peptide I Receptor −/− Mice , 1997, Diabetes.

[93]  K. Constantine,et al.  Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity. , 2009, Journal of medicinal chemistry.

[94]  Stephen R. Bloom,et al.  The inhibitory effects of peripheral administration of peptide YY3–36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal–brainstem–hypothalamic pathway , 2005, Brain Research.

[95]  J. Egan,et al.  Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. , 1994, Endocrinology.

[96]  M. Mattson,et al.  GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[97]  P. Brubaker,et al.  Printed in U.S.A. Copyright © 1999 by The Endocrine Society Role of the Vagus Nerve in Mediating Proximal Nutrient- Induced Glucagon-Like Peptide-1 Secretion* , 2022 .

[98]  Patrick M. Sexton,et al.  International Union of Pharmacology. XXXII. The Mammalian Calcitonin Gene-Related Peptides, Adrenomedullin, Amylin, and Calcitonin Receptors , 2002, Pharmacological Reviews.

[99]  A. Young,et al.  Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes , 2004, Regulatory Peptides.

[100]  W. Banks,et al.  Permeability of the blood-brain barrier to amylin. , 1995, Life sciences.

[101]  P. Sexton,et al.  Modulating receptor function through RAMPs: can they represent drug targets in themselves? , 2009, Drug discovery today.

[102]  D. Parkes,et al.  Enhanced amylin-mediated body weight loss in estradiol-deficient diet-induced obese rats. , 2010, Endocrinology.

[103]  Mohammad A Ghatei,et al.  Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. , 2005, Endocrinology.

[104]  J. Holst,et al.  Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor. , 2007, Bioorganic & medicinal chemistry letters.

[105]  G. Bertilsson,et al.  Peptide hormone exendin‐4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease , 2008, Journal of neuroscience research.

[106]  R. M. Gentry,et al.  Comparison of Fos induced in rat brain by GLP-1 and amylin , 1997, Regulatory Peptides.

[107]  R. DiMarchi,et al.  Synthesis and characterization of ester-based prodrugs of glucagon-like peptide 1. , 2010, Biopolymers.

[108]  P. Rorsman,et al.  Glucagon-Like Peptide I and Glucose-Dependent Insulinotropic Polypeptide Stimulate Ca2+-Induced Secretion in Rat α-Cells by a Protein Kinase A–Mediated Mechanism , 1997, Diabetes.

[109]  Soumitra S Ghosh,et al.  Amylin-Based Pharmacotherapy - Past, Present & Future , 2008 .

[110]  P. J. Larsen,et al.  Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem , 1997, Neuroscience.

[111]  C. Hölscher,et al.  Novel GLP‐1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain , 2011, Journal of neuroscience research.

[112]  D. Parkes,et al.  Multi-hormonal weight loss combinations in diet-induced obese rats: Therapeutic potential of cholecystokinin? , 2010, Physiology & Behavior.

[113]  D. Kendall,et al.  Exenatide once weekly for the treatment of type 2 diabetes , 2009 .

[114]  D. Drucker,et al.  Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. , 1999, Diabetes.

[115]  W. Colburn,et al.  Pharmacokinetics and Pharmacodynamics of AC137 (25,28,29 Tripro‐Amylin, Human) After Intravenous Bolus and Infusion Doses in Patients with Insulin‐Dependent Diabetes , 1996, Journal of clinical pharmacology.

[116]  Michael E. Lassman,et al.  Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice , 2009, Diabetes.

[117]  T. Rink,et al.  Dose-response for glucagonostatic effect of amylin in rats. , 1997, Metabolism: clinical and experimental.

[118]  B. Göke,et al.  Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying. , 2011, The Journal of clinical endocrinology and metabolism.

[119]  J. Holst,et al.  Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans? , 2010, The Journal of clinical endocrinology and metabolism.

[120]  N. Irwin,et al.  Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline. , 2010, European journal of pharmacology.

[121]  P. Wielinga,et al.  Modulation of the satiating effect of amylin by central ghrelin, leptin and insulin , 2007, Physiology & Behavior.

[122]  M. Schwartz,et al.  Leptin Regulation of the Anorexic Response to Glucagon-Like Peptide-1 Receptor Stimulation , 2006, Diabetes.

[123]  D. Drucker,et al.  A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. , 2004, Diabetes.

[124]  W. Langhans,et al.  Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. , 2009, Endocrinology.

[125]  S. Woods,et al.  The Role of CNS Glucagon-Like Peptide-1 (7-36) Amide Receptors in Mediating the Visceral Illness Effects of Lithium Chloride , 2000, The Journal of Neuroscience.

[126]  C. Weyer,et al.  Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. , 2001, Current pharmaceutical design.

[127]  R. Rudolph,et al.  Passing the baton in class B GPCRs: peptide hormone activation via helix induction? , 2009, Trends in biochemical sciences.

[128]  C. Anderson,et al.  Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression. , 2006, Endocrinology.

[129]  D. Drucker,et al.  An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. , 2008, Gastroenterology.

[130]  Manuel Desco,et al.  The expression of GLP‐1 receptor mRNA and protein allows the effect of GLP‐1 on glucose metabolism in the human hypothalamus and brainstem , 2005, Journal of neurochemistry.

[131]  P. Whitton,et al.  Glucagon‐like peptide 1 receptor stimulation as a means of neuroprotection , 2010, British journal of pharmacology.

[132]  W. Pan,et al.  Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier , 2002, Journal of Molecular Neuroscience.

[133]  Jung-Mo Ahn,et al.  Search for alpha-helical propensity in the receptor-bound conformation of glucagon-like peptide-1. , 2008, Bioorganic & medicinal chemistry.

[134]  D. Drucker,et al.  Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. , 1994, Endocrinology.

[135]  J. Habener,et al.  Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. , 1996, Endocrinology.

[136]  H. E. Maclean,et al.  Calcitonin Receptor Plays a Physiological Role to Protect Against Hypercalcemia in Mice , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[137]  D. D’Alessio,et al.  Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion. , 2008, The Journal of clinical endocrinology and metabolism.

[138]  N. Geary,et al.  Behaviorally specific inhibition of sham feeding by amylin , 1998, Peptides.

[139]  A. Joyner,et al.  Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene , 1996, Nature Medicine.

[140]  S. Woods,et al.  Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. , 2007, Endocrinology.

[141]  B. Roland,et al.  Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications. , 2009, Archives of neurology.

[142]  C. Weyer,et al.  Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. , 2004, Obesity research.

[143]  Kewei Chen,et al.  Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans , 2007, NeuroImage.

[144]  Laurence J Miller,et al.  Spatial Approximations between Residues 6 and 12 in the Amino-terminal Region of Glucagon-like Peptide 1 and Its Receptor , 2010, The Journal of Biological Chemistry.

[145]  D. Drucker,et al.  Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice , 2001, Virchows Archiv.

[146]  D. Drucker,et al.  Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. , 2005, Endocrinology.

[147]  M. Christensen,et al.  Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide? , 2010, Current diabetes reports.

[148]  T. Lutz,et al.  Amylin potently activates AP neurons possibly via formation of the excitatory second messenger cGMP. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

[149]  M. Wheeler,et al.  Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. , 2001, Biochemistry.

[150]  J. Holst,et al.  GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine , 2003, Regulatory Peptides.

[151]  R. Seth,et al.  Combined amylin–leptin treatment lowers blood pressure and adiposity in lean and obese rats , 2011, International Journal of Obesity.

[152]  E. Air,et al.  Acute 3rd-ventricular amylin infusion potently reduces food intake but does not produce aversive consequences , 2002, Peptides.

[153]  J. Holst,et al.  Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs , 2006, Scandinavian journal of gastroenterology.

[154]  Y. Hayashi,et al.  Mice deficient for glucagon gene-derived peptides display normoglycemia and hyperplasia of islet {alpha}-cells but not of intestinal L-cells. , 2009, Molecular endocrinology.

[155]  E. Tomás,et al.  GLP-1-derived nonapeptide GLP-1(28–36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice , 2011, Regulatory Peptides.

[156]  T. Lutz,et al.  The anorectic hormone amylin contributes to feeding-related changes of neuronal activity in key structures of the gut-brain axis. , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.

[157]  K. Fujioka,et al.  Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. , 2007, The Journal of clinical endocrinology and metabolism.

[158]  J. Holst The physiology of glucagon-like peptide 1. , 2007, Physiological reviews.

[159]  C. Weyer,et al.  Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. , 2007, American journal of physiology. Endocrinology and metabolism.

[160]  T. Kenakin,et al.  G Protein-Coupled Receptor Allosterism and Complexing , 2002, Pharmacological Reviews.

[161]  E. Scharrer,et al.  Subdiaphragmatic vagotomy does not influence the anorectic effect of amylin , 1995, Peptides.

[162]  B. Gallwitz,et al.  Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. , 1993, European journal of biochemistry.

[163]  E. Scharrer,et al.  Reduction of food intake in rats by intraperitoneal injection of low doses of amylin , 1994, Physiology & Behavior.

[164]  Christian Weyer,et al.  Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies , 2008, Proceedings of the National Academy of Sciences.

[165]  S. Bloom,et al.  Obesity treatment: novel peripheral targets. , 2009, British journal of clinical pharmacology.

[166]  J. Holst,et al.  Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas , 2008, Diabetologia.

[167]  B. Thorens Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[168]  H. Yoo-Warren,et al.  Cloning and functional expression of the human glucagon-like peptide-1 (GLP-1) receptor. , 1993, Endocrinology.

[169]  Daniel R. Thedens,et al.  Neuronal Receptor Activity–Modifying Protein 1 Promotes Energy Expenditure in Mice , 2011, Diabetes.